NCT06633341

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma

Detailed description

In this study, 30 patients with relapsed refractory T-lymphoma were proposed to undergo CD5 CAR-T Cells therapy. Under the premise that its safety has been clarified in previous studies, further observation and evaluation of the effectiveness of CD5 CAR-T Cells therapy for relapsed refractory T-lymphoma; At the same time, on the basis of expanding the sample size, more safety data on CD5 CAR-T Cells treatment for relapsed refractory T-lymphoma were accumulated.

Conditions

• T-lymphoblastic Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	CD5 CAR T-cells	Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion

Timeline

• Start date: 2024-10-20
• Primary completion: 2027-10-20
• Completion: 2027-10-20
• First posted: 2024-10-09
• Last updated: 2024-10-09

Locations

1 site across 1 country: China